Benzo[a]pyrene dial epoxide-induced 9p21 aberrations associated with genetic predisposition to bladder cancer

Genes Chromosomes and Cancer

Volumn 41, Issue 4, 2004, Pages 330-338

  Hazra, Aditi ^a,b   Grossman, H Barton ^a   Zhu, Yong ^a   Luo, Sherry ^a   Spitz, Margaret R ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; TOBACCO SMOKE; BENZO[A]PYRENE 7,8 DIHYDRODIOL 9,10 OXIDE; MUTAGENIC AGENT;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER RISK; CDKN2A GENE; CHEMICAL MUTAGENESIS; CHROMOSOME 9P; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; GENETIC RISK; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; BLADDER TUMOR; BLOOD; CHROMOSOME 9; CHROMOSOME ABERRATION; DRUG EFFECT; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC PREDISPOSITION; GENETICS; LYMPHOCYTE; METABOLISM; MIDDLE AGED; PILOT STUDY; SMOKING;

NICOTIANA TABACUM;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; AGED; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTES; MALE; MIDDLE AGED; MUTAGENS; PILOT PROJECTS; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 8444239375     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20093     Document Type: Article

References (51)

1. Bonassi S, Abbondandolo A, Camuri L, Dal Pra L, De Ferrai M, Degrassi F, Forni A, Lamberti L, Lando C, Padovani P, Sbrana I, Vecchio D, Puntoni R. 1995. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet 79:133-135.
2. Cairns P, Shaw ME, Knowles MA. 1993. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8:1083-1085.
3. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Bucler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D. 1995. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11:210-212.
4. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones, C., Housman, DF. 1990. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520.
5. Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI, Sidransky D. 2000. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89:514-518.
6. Coquelle A, Pipiras E, Toledo F, Buttin C, Debatisse M. 1997. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89:215-225.
7. Czermak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, Luthra R, Logothetis C, Von Eschenbach AC, Grossman HB, Benedict WK, Batsakis JG. 1999. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 18:1185-1196.
8. Czerniak B, Li L, Chaturvedi V, Ro JY, Johnston DA, Hodges S, Benedict WF. 2000. Genetic modeling of human urinary bladder carcinogenesis. Genes Chromosomes Cancer 27:392-402.
9. Denissenko MF, Pao A, Tang M. Pfeifer GP. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274:430-432.
10. Devlin J, Keen AJ, Knowles MA. 1994. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA. Oncogene 9:2757-2760.
11. Egeli U, Karadag MK, Tunca B, Ozyardimci N. 1997. The expression of common fragile sites and genetic predisposition to squamous cell lung cancers. Cancer Genet Cytogenet 95:153-158.
12. Fadl-Elmula I, Gorunova L, Mandahl N, Elfving P, Lundgren R, Mitelman F, Heim S. 2000. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 29:256-265.
13. Habuchi T, Devlin J, Elder PA, Knowles MA. 1995. Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 11:1671-1674.
14. Hagmar L, Brogger A, Hansteen I, Heim S, Hogstedt B, Knudsen L, Lambert B, Linnainmaa K, Mitelman F, Nordenson I, Reuterwall C, Salomaa S, Skerfving S, Sorsa M. 1994. Cancer risk in humans predicted by increased levels of chromosome aberration in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 54:2919-2922.
15. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Kuechel R. 1999. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154:721-727.
16. Hopman AH, Moesker O, Smeets AW, Pauwels RP, Vooijs GP, Ramackers FC. 1991. Numerical chromosome 1, 7, 9, and 11 aberration; in bladder cancer detected by in situ hybridization. Cancer Res 51:644-651.
17. Jones PA. 1993. Pathways in the development und progression of bladder cancer: new correlations between clinical observations and molecular mechanisms. Scmin Urol 11:177-192.
18. Kallioniemi A, Kallioniemi OP, Citro G, Sauter G, DeVrics S, Kerschmann R, Caroll P, Waldman F. 1995. Identification of gains and losses of ONA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 12:213-219.
19. Keen AJ, Knowles MA. 1994. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 9:2083-2088.
20. Lee MH, Yang HY. 2001. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 58:1907-1922.
21. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. 1987. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235:1394-1399.
22. Linnenbach AJ, Pressler LB, Seng BA, Kimmel RS, Tomaszewski JE, Malkowicz SB. 1993. Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. Hum Mol Genet 2:1407-1411.
23. Lowe SW, Sherr CJ. 2003. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Des 13:77-83.
24. Mao IV, Lee JS, KuMe JM, Fan YH, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC, Kemp BL, Khuri FR, Walsh GL, Hittelman WN, Hong WK. 1997. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89:857-862.
25. Marcus PM, Vineis P, Rothman N. 2000. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmaeogenetics 2000;10:115-122
26. Nakayama T, Kanedo M, Kodama M, Nagata C. 1985. Cigarette smoke induces DNA single-strand breaks in human cells. Nature 314:462-464.
27. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pwllicer I, Dalhagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C. 1995. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 87:1524-1529.
28. Ozen H. 1998. Bladder cancer. Curr Opin Oncol 10:273-278.
29. Pathak S, Goodacre A. 1986. Specific chromosome anomalies and predisposition to human breast, renal cell, and colorectal carcinoma. Cancer Genet Cytogenet 19:29-36.
30. Poddighe PJ, Bringuier PP, Vallinga M, Schalken JA, Ramackers FC, Hopman AH. 1996. Loss of chromosome 9 in tissue sections of transitional cell carcinomas as detected by interphase cytogenetics. A comparison with RFLP analysis. J Pathol 179:169-176.
31. Ruppert JM, Tokino K, Sidransky D. 1993. Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 53:5093-5095.
32. Sanchez-Cespedes M, Decker PA, Doffek KM, Esteller M, Westra WH, Alawi KA, Herman JG, Demeure MJ, Sidransky D, Ahrendt SA. 2001. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res 61:2092-2096.
33. Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldman FM. 1995. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer, Int J Cancer 64:99-103.
34. Seetharam S, Kraemer KH, Waters HL, Seidman MM. 1991. Ultraviolet mutational spectrum in a shuttle vector propagated in xeroderma pigmentosum lymphoblastoid cells and fibroblasts. Mutat Res 254:97-105.
35. Sellers TA, Potter JD, Bailey-Wilson JE, Rich SS, Rothschild H, Elsta RC. 1992. Lung cancer detection and prevention: evidence for an interaction between smoking and genetic predisposition. Cancer Res 52:2696-2697.
36. Simoneau M, Ahoulkassim TO, LaRue H, Rousseau F, Fradet Y. 1999. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 18:157-163.
37. Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y. 2000. Chromosome 9 deletions and reeurrenee of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene 19:6317-6323.
38. Smeets W, Schapers R, Hopman A, Pauwels R, Ramaekers F. 1991. Numerical chromosome 1, 7, 9, and 11 aberrations in bladder cancer detected by in situ hybridization. Cancer Res 51:644-651.
39. Sundareshan TS, Augustus M. 1995. Expression of common fragile sites in lymphocytes of Wilms tumor in patients, their parents, and siblings: a study of ten families. Cancer Genet Cytogenet 84:51-55.
40. Udumudi A, Jaiswal M, Rajeswari N, Desai N, Jain S, Balakrishna N, Rao KV, Ahuja YR. 1998. Risk assessment in cervical dysplasia patients by single cell gel electrophoresis assay: a study of DNA damage and repair. Mutat Res 412:195-205,
41. U.S. Surgeon General. 1982. NIH Publication 82-50179. Washington, DC: U.S. Department of Health and Human Services.
42. van der Riet P, Nawroz H, Hruban RH, Corio R, Tokino K, Koch W, Sidransky D. 1994. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54:1156-1158.
43. Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu X. 2003. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair 2:901-908.
44. Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA. 1995. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4:1569-1577.
45. Wistuba II, Lam S, Behrens C, Virmani AK, Pong KM, LeRiche J, Samet JM, Srivastava S, Minna JD, Gazdar AF. 1997. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 89:1366-1373.
46. Wu X, Hsu TC, Annegers JF, Amos CI, Fueger JJ, Spitz MR. 1995b. A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer patients. Cancer Res 55:557-561.
47. Wu X, Gu J, Hsu TC, Hong W K, Shi H, and Spitz MR. 1997a. Differential sensitivity to benzo[a]pyrene-diol-epoxide (BPDE) as a marker of lung cancer susceptibility [Abstract]. Proc Amer Assoc Cancer Res 38:618.
48. Yunis JJ, Ramsay N. 1978. Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child 132:161-163.
49. Yunis JJ, Ramsay N. 1980. Familial occurrence of the aniridia Wilm's tumor syndrome with deletion 11p13-14.1. J Pediatr 96:1027-1030.
50. Yunis JJ, Soreng AL. Constitutive fragile sites and cancer. 1984. Science 226:1199-204.
51. Zhu Y, Spitz MR, Strom S, Tomlinson GE, Amos CI, Minna JD, Wu X. 2002. A case-control analysis of lymphocytic chromosome 9 aberrations in lung cancer. Int J Cancer 102:536-540.